A Phase Ib Study of SEL120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
Phase of Trial: Phase I
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs SEL-120 (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; First in man
- Sponsors Ryvu Therapeutics
- 10 Dec 2019 Trial design released in the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 06 Nov 2019 According to Ryvu Therapeutics media release, data from this study will be presented at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando, FL, taking place from December 7-10, 2019.
- 06 Sep 2019 According to a Selvita media release, the first patient has been enrolled and dosed in this trial. Preliminary results anticipated to share with the oncology community in 2020.